FDA Approves T-DXd with Pertuzumab for Breast Cancer Treatment
Okay, here’s a breakdown of the references provided, formatted for clarity:
References:
- FDA approval of Fam-Trastuzumab Deruxtecan-nxki and Pertuzumab:
* Source: U.S.Food and Drug Administration (FDA)
* Link: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive
* Focus: Approval for the treatment of unresectable or metastatic HER2-positive breast cancer.
- DESTINY-Breast09 Clinical Trial:
* title: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
* Identifier: NCT04784715
* Source: ClinicalTrials.gov
* Link: https://clinicaltrials.gov/study/NCT04784715
* Updated: November 12,2025
* Accessed: December 15,2025
- Emerging Data from DESTINY-Breast Trials:
* Author: Gerlach A.
* Source: Pharmacy Times
* (The full citation is incomplete in the provided text.)
key Takeaways:
* The references relate to the use of trastuzumab deruxtecan (T-DXd), possibly in combination with pertuzumab, for HER2-positive breast cancer.
* The DESTINY-Breast09 trial is a key study evaluating this treatment approach.
* the FDA has approved this combination therapy based on clinical trial data.